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We investigated the clinical usefulness of the revised 2010 Clinical and Laboratory Standards Institute (CLSI) breakpoints for
Escherichia coli and Klebsiella spp. Of 2,623 patients with bacteremia caused by E. coli or Klebsiella spp., 573 who had been treated
appropriately with cephalosporin based on the CLSI 2009 guidelines were enrolled. There were no differences in the rates of
treatment failure or mortality between the appropriately and inappropriately treated groups according to the CLSI 2010 guidelines.
Additionally, in the matched case-control analysis, the treatment failure rate was higher in bacteremic patients with extended-
spectrum 𝛽-lactamase- (ESBL-) producing but cephalosporin-susceptible organisms than in those with ESBL-nonproducing
isolates when patients with urinary tract infections were excluded (44% and 0%, resp., 𝑃 = 0.026). In patients with bacteremia
caused by E. coli or Klebsiella spp., the revised CLSI 2010 guidelines did not lead to poorer outcomes. However, ESBL production
appeared to be associated with poor clinical outcomes in patients with bacteremia from sources other than the urinary tract.
1. Introduction
In January 2010, revised cephalosporin breakpoints were
published by the Clinical and Laboratory Standards Institute
(CLSI) (Table 1) [1]. These new breakpoints were determined
using the pharmacokinetic-pharmacodynamic properties of
antimicrobial agents and minimal inhibitory concentration
(MIC) distributions for relevant organisms [2, 3]. However,
there were limited clinical data to support the efficacy
of these new guidelines [4, 5]. On adhering to the CLSI
2010 guidelines, carbapenems will most likely be used as
alternative antimicrobial agents owing to an increase in
cephalosporin resistance, which will result in an increase in
carbapenem administration [6]. Additionally, routine testing
for extended-spectrum 𝛽-lactamase (ESBL) is no longer
considered necessary before reporting susceptibility profiles
that guide clinical management [1]. However, whether ESBL
testing is important to ensure appropriate therapy [7] and to
document local ESBLprevalence data, so that empiric therapy
is as targeted as possible [8], is a matter of debate.
Therefore, we investigated the clinical usefulness of the
revised breakpoints in the CLSI 2010 guidelines for the treat-
ment of bacteremia caused by Enterobacteriaceae, specifically
Escherichia coli and Klebsiella spp., compared with the CLSI
2009 guidelines.
2. Materials and Methods
2.1. Subjects and Study Design. We conducted a retrospec-
tive cohort study to evaluate the clinical usefulness of
the CLSI 2010 guidelines for the treatment of bacteremia
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Table 1: Minimum inhibitory concentration and disk diffusion interpretive breakpoints for several cephalosporins established in January
2009 and January 2010 by the Clinical and Laboratory Standards Institute.
Agent
MIC breakpoints (𝜇g/mL) Disk diffusion breakpoints (mm)
CLSI 2009 (M100-S19) CLSI 2010 (M100-S20) CLSI 2009 (M100-S19) CLSI 2010 (M100-S20)
S I R S I R S I R S I R
Cefazolin ≤8 16 ≥32 ≤1 2 ≥4 ≥18 15–17 ≤14 NA NA NA
Cefotaxime ≤8 16–32 ≥64 ≤1 2 ≥4 ≥23 15–22 ≤14 ≥26 23–25 ≤22
Ceftizoxime ≤8 16–32 ≥64 ≤1 2 ≥4 ≥20 15–19 ≤14 ≥25 22–24 ≤21
Ceftriaxone ≤8 16–32 ≥64 ≤1 2 ≥4 ≥21 14–20 ≤13 ≥23 20–22 ≤19
Ceftazidime ≤8 16 ≥32 ≤4 8 ≥16 ≥18 15–17 ≤14 ≥21 18–20 ≤17
MIC, minimum inhibitory concentration; CLSI, Clinical and Laboratory Standards Institute; NA, not available.
caused by E. coli or Klebsiella spp. A medical record review
was conducted for 2,623 patients who were treated for E.
coli or Klebsiella spp. bacteremia between January 2006
and December 2010 at Severance Hospital, a tertiary-care
teaching hospital with more than 2000 beds. The patients
who were appropriately treated with extended-spectrum
cephalosporins (ceftazidime, ceftriaxone, cefotaxime, or cef-
piramide) were included and divided into 2 groups based
on the appropriateness of antimicrobial therapy according to
the CLSI 2010 guidelines (Figure 1). Clinical outcomes were
compared between the 2 groups with respect to the class of
antimicrobials used and the microbial species. Patients <18
years of age at the time of bacterial isolation and patients who
received inappropriate definitive antimicrobial therapy based
on the CLSI 2009 guidelines were excluded.
In addition, a matched case-control study was con-
ducted to determine the clinical usefulness of ESBL test-
ing. The clinical outcomes of sepsis patients with ESBL-
producing cephalosporin-susceptible isolates who received
a cephalosporin as the appropriate definitive antimicrobial
treatment as per the CLSI 2010 guidelines were compared to
matched subjects with sepsis caused by ESBL-nonproducing
isolates (in ratio of 1 : 2). The 2 groups were matched for age,
source of infection, and Sequential Organ Failure Assessment
(SOFA) score [9].
The following variables identified from medical records
and the computerized database in the clinical microbiology
laboratory were assessed: age, gender, underlying disease,
predisposing conditions, possible route of infection, labora-
tory data at the time of bacteremia onset and 72 hours after
definitive antimicrobial therapy, results of antimicrobial sus-
ceptibility testing, antimicrobial regimen, severity of illness
as determined by the SOFA score, and clinical outcome. The
primary outcome measures were treatment failure and all-
cause 28-day mortality rate. This study was approved by the
Institutional Review Board (IRB) of Severance Hospital (IRB
#4-2010-0522), and the need for written informed consent
from all participants was waived by the approving IRB.
2.2. Definitions. Significant bacteremia was defined as isola-
tion ofE. coli orKlebsiella spp. in≥1 separately obtained blood
culture and the presence of clinical features compatible with
fever and sepsis syndrome [10].Hospital-acquired bacteremia
was defined as a positive blood culture taken from a patient
who demonstrated clinical evidence of infection ≥48 hours
after admission [11]. The route of infection was determined
based on isolation of the organism from the presumed entry
point in conjunction with clinical evaluation [12]. Septic
shock was defined as sepsis associated with evidence of
organ hypoperfusion and either a systolic blood pressure of
<90mmHg or >30mmHg less than baseline or required use
of a vasopressor to maintain adequate blood pressure [13].
All underlying diseases, including cardiovascular disease,
chronic renal disease, chronic liver disease, and chronic lung
disease, were defined according to the International Classifi-
cation of Disease, 10th Revision [14].The Charlson index was
used to assess the burden of chronic disease [15]. Definitive
antimicrobial therapy was defined as antimicrobial therapy
that began or continued on the day that the antibiogram
results were reported to the clinicians, which was not later
than 120 h after the initial positive blood sample had been
drawn [16]. Susceptibility to cephalosporins was defined as
in vitro susceptibility to cefotaxime or ceftazidime. Antimi-
crobial therapy was considered appropriate if the treatment
regimen included antibiotics that were susceptible [16] and
the dosage and route of antimicrobial administration were
in accordance with current standards of care and their renal
function [1, 17]. Treatment failure was defined as persistent
fever, septic shock, or bacteremia 72 hours after starting
definitive antimicrobial therapy [16]. Deathwas considered to
be related to bacteremia if the patient diedwithin 28 days after
receiving treatment, unless clinical data clearly suggested that
death was due to another cause.
2.3. Microbiological Tests. Isolates were identified using one
of two conventional biochemical methods: ATB 32 GN
or VITEK 2 systems (bioMerieux, Marcy-l’Etoile, France).
Antimicrobial susceptibilities were determined using the
disc-diffusion method or a VITEK-2 N131 card (bioMerieux,
Hazelwood, MO, USA). The results were interpreted accord-
ing to the CLSI 2009 and 2010 guidelines [1, 17]. ESBL pro-
ductionwas determined using a double-disk potentiation test
with amoxicillin-clavulanic acid and cefotaxime, ceftazidime,
or cefepime or by positive results for ESBL on using the
VITEK-2 N131 card.
2.4. Statistical Analysis. Student’s t-tests were used to com-
pare continuous variables, and 𝜒2 or Fisher’s exact tests were
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Figure 1: Flowchart of patient inclusion and subsequent treatment.
used to compare categorical variables. All 𝑃 values were
two-sided, and 𝑃 values < 0.05 were considered statistically
significant. All statistical analyses were performed using SAS
version 9.1.3 (SAS Institute, Cary, NC, USA).
3. Results
3.1. Baseline Characteristics and Microbiologic Data of the
Subjects. Of the 2,623 patients with E. coli or Klebsiella spp.
bacteremia, 573 patients were eligible for this study (Figure 1).
Table 2 shows the demographic and clinical characteristics of
the patients. The median age was 65.5 years (range, 24–92
years), and 50.8% of the subjects were men. Of the 573 cases
of bacteremia, 81.7% were community acquired, 18.3% were
hospital acquired, 45.9% were associated with underlying
malignancy, and 29.5% were associated with diabetes melli-
tus. The most frequent cause of sepsis was pancreatobiliary
infection (46.6%), followed by urinary tract infection (UTI)
(28.6%) and primary bacteremia (9.4%). The numbers of
isolated E. coli and Klebsiella spp. were 360 (62.8%) and 213
(37.2%), respectively. Of these isolates, 1.7% (10/573) were
ESBL producers.
3.2. Usefulness of the Revised Cephalosporin Breakpoints in the
CLSI 2010 Guidelines for the Treatment of Bacteremia Caused
by ESBL-Nonproducing E. coli and Klebsiella spp. A total of
353 and 210 cases of sepsis caused by ESBL-nonproducing
E. coli and Klebsiella spp., respectively, were treated with a
cephalosporin as appropriate definitive antimicrobial therapy
according to the CLSI 2009 guidelines. Table 3 shows the
clinical characteristics and outcomes of these patients. Treat-
ment with cephalosporin was considered to be inappropriate
by the CLSI 2010 guidelines in 53 (53/353, 15.0%) and 38
(38/210, 18.1%) patients with identified E. coli and Klebsiella
spp. isolates, respectively. Baseline characteristics did not
differ between groups of appropriately treated and inappro-
priately treated patients, according to the 2010 guidelines.
Treatment failure rates did not differ significantly between
the appropriately and inappropriately treated groups as well
(10.3% and 15.1% for E. coli (𝑃 = 0.308), resp.; 14.0% and
23.7% for Klebsiella spp. (𝑃 = 0.136), resp.). Additionally,
there were no differences between the 2 groups in terms of
28-day mortality rates (2.7% and 7.5% for E. coli (𝑃 = 0.089),
resp.; 8.7% and 2.6% for Klebsiella spp. (𝑃 = 0.315), resp.).
3.3. Matched Case-Control Study of Patients Treated with
a Cephalosporin as an Appropriate Definitive Antimicrobial
Treatment under the Revised CLSI Guidelines. In patients
treated with a cephalosporin as appropriate definitive antimi-
crobial therapy according to the revised CLSI 2010 guide-
lines, a total of 10 patients with ESBL-producing isolates
were identified (Table 4). There were no significant differ-
ences between the ESBL-producing and ESBL-nonproducing
groups in baseline characteristics (Table 5). The treatment
failure rate in the ESBL-producing group was 30.0% (3/10),
while 10.0% (2/20) of the ESBL-nonproducing group failed in
treatment (𝑃 = 0.300). Additionally, there were no significant
differences between the ESBL-producing and -nonproducing
groups in 28-day mortality rates (10% [1/10] versus 5% [1/20],
𝑃 = 1.000).
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Table 2: Demographic and clinical characteristics of 573 patients
with E. coli or Klebsiella spp. Bacteremia.
Variables Number (%)
Mean age (range, years) 65.51 (24–92)
Male 291 (50.8)
Hospital acquired 105 (18.3)
Community acquired 468 (81.7)
Underlying disease
Malignancy
Solid 249 (43.5)
Hematologic 14 (2.4)
Transplantation
Solid 5 (0.9)
Hematopoietic stem cell 0 (0.0)
Diabetes 169 (29.5)
Cardiovascular disease 261 (45.5)
Chronic lung disease 4 (0.7)
Chronic renal disease 23 (4.0)
Chronic liver disease 58 (10.1)
HIV infection 1 (0.1)
Route of infection
Urinary tract infection 164 (28.6)
Liver abscess 40 (7.0)
Pancreatobiliary infection 267 (46.6)
Pulmonary infection 17 (3.0)
Peritonitis 18 (3.1)
Primary bacteremia 54 (9.4)
Other 13 (2.3)
Charlson index, mean ± SD 2.63 ± 2.278
SOFA score, mean ± SD 3.02 ± 2.493
ESBL-producing isolates 10 (1.7)
28-day mortality 29 (5.1)
ESBL, extended-spectrum 𝛽-lactamase; HIV, human immunodeficiency
syndrome; ICU, intensive care unit; SOFA, Sequential Organ Failure Assess-
ment.
We conducted a subgroup analysis of the matched case
controls excluding patients with UTIs. The case group
included 7 patients with ESBL-producing isolates that were
matched according to age, origin of infection, and SOFA
score with ESBL-nonproducing isolates (1 : 2 ratio) (Table 5).
The treatment failure rates were 42.9% (3/7) and 0.0% (0/14)
in the ESBL-producing and ESBL-nonproducing groups,
respectively (𝑃 = 0.026). However, the 28-day mortality rates
were not significantly different between the groups (14.3%
[1/7] versus 7.1% [1/14], 𝑃 = 1.000).
4. Discussion
In our study, the use of the revised CLSI 2010 guidelines
did not lead to poorer clinical outcomes for patients treated
with cephalosporins for E. coli andKlebsiella spp. bacteremia,
compared with the CLSI 2009 guidelines. This is despite
the fact that the revised breakpoints for extended-spectrum
cephalosporins in the CLSI 2010 guidelines were likely to
result in lower susceptibility rates and, in particular, routine
testing for ESBL was no longer considered necessary, which
led to our hypothesis that the revised guidelines would lead
to poorer outcomes than the previous guidelines.
A recent study evaluating the effects of the clinical
breakpoint changes in the revised CLSI 2010 guidelines on
antibiotic susceptibility test reporting of gram-negative bacilli
[6] reported no significant changes in the antibiotic suscep-
tibility rates of E. coli or Klebsiella spp. to third-generation
cephalosporins. Further, the majority of the changes that
occurred were shifts from “susceptible” to “intermediate”
susceptibility, indicating that, in fact, there may be little
change in microbiologic susceptibility with the 2010 revised
breakpoints.
Despite a lack of statistical significance in the present
study, there were potentially clinically significant changes in
outcomes. For example, in patients with bacteremia caused
by ESBL-nonproducing E. coli and Klebsiella spp. treated
with a cephalosporin according to the new CLSI breakpoints,
the 28-day mortality rates, based on the appropriateness of
treatment, were 2.7% (appropriate) and 7.5% (inappropriate)
for E. coli and 8.7% (appropriate) and 2.6% (inappropriate)
forKlebsiella spp. However, these resultsmay have been influ-
enced by fewer occurrences at the endpoints. Additionally, in
regards to treatment failure, if the whole series is considered,
a higher proportion of patients inappropriately treated failed
(18.6% [17/91] versus 11.6% [55/472], 𝑃 = 0.07). Thus, even
if there was no statistically significant association between
appropriateness of therapy and clinical failure, there was a
trend towards significance between them.
The revised CLSI guidelines suggest that, with the new
breakpoints, routine ESBL testing is no longer necessary
before reporting results that will guide clinical management
[1]. In this study, we also found that, in patients treated
with a cephalosporin as the appropriate definitive antimicro-
bial therapy under the revised CLSI 2010 guidelines, ESBL
production did not influence clinical outcomes in patients
with E. coli and Klebsiella spp. bacteremia. However, many
investigators still debate whether ESBL testing is important
to increase the probability of success [7]. In addition, when
we excluded patients with UTIs as the source of bacteremia,
the treatment failure rate was significantly higher in the group
with bacteremia due to ESBL-producing isolates than in the
group with bacteremia due to ESBL-nonproducing isolates.
Thus, our data suggest that ESBL testing may be consid-
ered for patients with bacteremia from sources other than
UTI. This supports previous reports that have shown that
patients with susceptible MICs and ESBL-producing isolates
frequently experienced antimicrobial treatment failure [5, 18,
19] and that, in bacteremic patients with ESBL-producing
isolates, UTI was an independent determinant of reduced
mortality rates [20].
Our study has certain limitations. First, the sample of
patients with E. coli and Klebsiella spp. bacteremia in this
study was collected from a single center; this may limit the
generalizability of the results to other centers. Second, as in all
retrospective studies, there is potential for bias and inaccurate
data collection. Third, despite a large initial study sample,
subanalysis was conducted in a small sample of patients.
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Table 3: Clinical characteristics and outcomes of patients with bacteremia caused by ESBL-nonproducing Enterobacteriaceaetreated with a
cephalosporin according to the new CLSI breakpoints.
Variables
Number (%) of patients with bacteremia Number (%) of patients with bacteremia
caused by E. coli: caused by Klebsiella spp.:
Appropriate Tx. Inappropriate Tx.
𝑃 value Appropriate Tx. Inappropriate Tx. 𝑃 value
(𝑁 = 300) (𝑁 = 53) (𝑁 = 172) (𝑁 = 38)
Age (years), mean ± SD 66.06 ± 12.81 63.58 ± 13.59 0.199 65.21 ± 11.72 65.87 ± 11.72 0.753
Male 122 (40.7) 24 (45.3) 0.529 104 (60.5) 29 (76.3) 0.032
Hospital acquired 43 (14.3) 9 (17.0) 0.616 43 (25.0) 5 (13.2) 0.116
Community acquired 257 (85.7) 44 (83.0) 0.616 129 (75.0) 33 (86.8) 0.116
Underlying disease
Malignancy
Solid 120 (40.0) 22 (41.5) 0.836 89 (51.7) 14 (36.8) 0.096
Hematologic 7 (2.3) 1 (1.9) 1.000 3 (1.7) 1 (2.6) 0.717
Transplantation
Solid 4 (1.3) 1 (1.9) 0.558 0 (0.0) 0 (0.0)
Hematopoietic stem cell 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Diabetes 90 (30.0) 11 (20.8) 0.170 56 (32.6) 10 (26.3) 0.453
Cardiovascular disease 147 (49.0) 26 (49.1) 0.994 69 (40.1) 16 (42.1) 0.821
Chronic lung disease 1 (0.3) 0 (0.0) 1.000 3 (1.7) 0 (0.0) 1.000
Chronic renal disease 11 (3.7) 1 (1.9) 0.701 5 (2.9) 3 (7.9) 0.146
Chronic liver disease 28 (9.3) 4 (7.5) 0.800 24 (14.0) 2 (5.3) 0.179
HIV infection 1 (0.3) 0 (0.0) 1.000 0 (0.0) 0 (0.0)
Charlson index 2.53 ± 2.24 2.28 ± 1.98 0.446 2.97 ± 2.47 2.21 ± 2.04 0.078
Source of infection
Urinary tract infection 118 (39.3) 21 (39.6) 0.968 15 (8.7) 6 (15.8) 0.189
Liver abscess 7 (2.3) 1 (1.9) 1.000 26 (15.1) 7 (18.4) 0.612
Pancreatobiliary infection 132 (44.0) 24 (45.3) 0.862 88 (51.2) 18 (47.4) 0.672
Pulmonary infection 4 (1.3) 1 (1.9) 0.559 8 (4.7) 4 (10.5) 0.236
Peritonitis 7 (2.3) 2 (3.8) 0.629 9 (5.2) 0 (0.0) 0.369
Primary bacteremia 26 (8.7) 3 (5.7) 0.595 20 (11.6) 3 (7.9) 0.774
Others 6 (2.0) 1 (1.9) 4 (2.3) 0 (0.0)
SOFA score, mean ± SD 2.75 ± 2.316 2.79 ± 2.315 0.910 3.39 ± 2.737 3.47 ± 2.275 0.860
Antimicrobials
Ceftazidime 7 (2.3) 0 (0.0) 0.600 2 (1.2) 1 (2.6) 0.452
Cefpiramide 104 (34.7) 17 (32.1) 0.806 72 (41.9) 11 (28.9) 0.141
Cefotaxime 18 (6.0) 4 (7.5) 0.756 16 (9.3) 5 (13.2) 0.549
Ceftriaxone 171 (57.0) 32 (60.4) 0.660 82 (47.7) 21 (55.3) 0.397
Clinical outcomes
Treatment failure after 72 hr 31 (10.3) 8 (15.1) 0.308 24 (14.0) 9 (23.7) 0.136
28-day mortality 8 (2.7) 4 (7.5) 0.089 15 (8.7) 1 (2.6) 0.315
CLSI, Clinical and Laboratory Standards Institute; ESBL, extended-spectrumbeta lactamase;E. coli,Escherichia coli; HIV, human immunodeficiency syndrome;
ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment; SD, standard deviation; Tx., treatment.
Further prospective studies conducted in multiple centers
with larger samples are necessary to appraise the clinical
usefulness of the revised CLSI breakpoints. In addition, the
appropriateness of the initial empirical antimicrobials could
have had an influence on the clinical outcomes of this study.
However, because 1.2% (6/482) of the appropriate definitive
antimicrobials had inappropriate empirical antimicrobials
and only 3.3% (3/91) of the inappropriate definitive antimi-
crobials had appropriate empirical antimicrobials, we think
that the initial empirical antimicrobials were likely to have
little influence on the clinical outcomes in this study. Lastly, in
our hospital, antimicrobial susceptibilities were determined
using the disc-diffusion method only until May 2009, and
since then, MICs were measured and reported by using
VITEK-2 system. Thus, we were not able to describe the
distribution of the MICs of organisms.
5. Conclusions
In conclusion, in patients with bacteremia caused by E. coli
or Klebsiella spp., treatment according to the revised CLSI
2010 guideline did not lead to poorer outcomes, compared
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Table 5: Clinical characteristics and outcomes of patients treated with a cephalosporin as an appropriate definitive antimicrobial treatment
under the revised CLSI guidelines in ESBL-producing or nonproducing E. coli and Klebsiella spp. bacteremia.
Variables
Patients with bacteremia caused by Non-UTI Patients with bacteremia caused by
Enterobacteriaceae Enterobacteriaceae
ESBL-producing Non-ESBL-producing
𝑃 value ESBL-producing Non-ESBL-producing 𝑃-value
𝑁 = 10, 𝑛 (%) 𝑁 = 20, 𝑛 (%) 𝑁 = 7, 𝑛 (%) 𝑁 = 14, 𝑛 (%)
Age (years), mean ± SD 64.261 ± 12.976 65.15 ± 11.47 0.849 60.34 ± 12.603 63.70 ± 10.265 0.519
Male 7 (70.00) 12 (60.00) 0.702 6 (85.7) 10 (71.4) 0.624
Organism
E. coli 7 (70.00) 14 (70.00) 1.000 5 (71.4) 8 (57.1) 0.192
K. pneumonia 1 (10.00) 6 (30.00) 0.372 1 (14.3) 6 (42.9)
K. oxytoca 2 (20.00) 0 (0.00) 0.103 1 (14.3) 0 (0.00)
Hospital acquired 5 (50.00) 7 (35.00) 0.461 4 (57.1) 5 (35.7) 0.397
Community acquired 5 (50.00) 13 (65.00) 3 (42.9) 9 (64.3)
Underlying disease
Malignancy
Solid 5 (50.00) 10 (50.00) 1.000 4 (57.1) 9 (64.3) 1.000
Hematologic 2 (20.00) 1 (5.00) 0.251 2 (28.6) 1 (7.1) 0.247
Transplantation
Solid 0 (0.00) 2 (10.00) 0.540 0 (0.0) 2 (14.3) 0.533
Hematopoietic stem cell 0 (0.00) 0 (0.00) 0 (0.0) 0 (0.0)
Diabetes 2 (20.00) 7 (35.00) 0.675 0 (0.0) 5 (35.7) 0.123
Cardiovascular disease 2 (20.00) 8 (40.00) 0.420 0 (0.0) 4 (28.6) 0.255
Chronic lung disease 0 (0.00) 1 (5.00) 1.000 0 (0.00) 1 (7.1) 1.000
Chronic renal disease 2 (20.00) 1 (5.00) 0.251 1 (14.3) 1 (7.1) 1.000
Chronic liver disease 0 (0.00) 1 (5.00) 1.000 0 (0.00) 1 (7.1) 1.000
Source of infection
Urinary tract infection 3 (30.00) 6 (30.00) 1.000
Pancreatobiliary infection 5 (50.00) 10 (50.00) 1.000 5 (71.4) 10 (71.4) 1.000
Primary bacteremia 2 (20.00) 4 (20.00) 1.000 2 (28.6) 4 (28.6) 1.000
SOFA score, mean ± SD 4.300 ± 3.653 4.300 ± 3.556 1.000 5.71 ± 3.450 5.71 ± 3.315 1.000
Antimicrobials
Cefpiramide 4 (40.0) 5 (25.0) 1.000 3 (42.9) 5 (35.7) 1.000
Cefotaxime 1 (10.0) 3 (15.0) 1.000 1 (14.3) 2 (14.3) 1.000
Ceftriaxone 5 (50.0) 12 (60.0) 1.000 3 (42.9) 7 (50.0) 1.000
Clinical outcomes
Treatment failure after 72 hr 3 (30.00) 2 (10.00) 0.300 3 (42.9) 0 (0.0) 0.026
28-day mortality 1 (10.00) 1 (5.00) 1.000 1 (14.3) 1 (7.1) 1.000
CLSI, Clinical and Laboratory Standards Institute; ESBL, extended-spectrumbeta lactamase;E. coli,Escherichia coli; HIV, human immunodeficiency syndrome;
ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment; SD, standard deviation; Tx., treatment.
to treatment according to the CLSI 2009 guideline. However,
ESBL production appeared to be associated with poor clinical
outcomes in patients with bacteremia from sources other
than the urinary tract.
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